KUSURI (the Japanese word for Medicine) is a Continuing medical Education Programme developed by Daiichi Sankyo Ireland under the direction of an esteemed panel of experts in the Areas of Cardiology and care of the Elderly.
The KUSURI initiative is aimed at promoting excellence in the diagnosis and management of Atrial Fibrillation with the ultimate goal of reducing both the incidence and recurrence of Stroke in Ireland.
Atrial fibrillation (AF) is a common cardiac rhythm disturbance and increases in prevalence with age particularly the population 65 years and over. Admission to hospital can be frequent and AF is associated with a five-fold increased risk of stroke, a three-fold risk of heart failure and two-fold increased risk of both dementia and mortality. In Ireland, the population 65 years and over is increasing by approximately 20,000 each year for the foreseeable future and as a result AF is a growing public health concern.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
If you or a patient of yours experiences any adverse effects whilst taking a Daiichi Sankyo product, please report the event to:
Daiichi Sankyo Ireland Limited
Unit 29, Block 3
01 489 3000